Announced Mon, 22 Jun · 18:41 IST
ESOP 2026 approved covering 20 lakh shares; INR 70 Cr collateral for Saudi arm
Capital Market Events View source PDF
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-6.5%1-day move
₹727.50
prior close
₹726.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.3-1.3-1.3-1.6-6.5-8.6-9.6-6.6-7.2-8.3-12.1-7.1——
Up moveDown movePending
AI summary
Board approved the ESOP 2026 scheme covering up to 20,06,814 equity shares (about 2% of paid-up capital) of Rs 2 face value, subject to shareholder and regulatory approvals. Also approved collateral support of up to INR 70 Crore for its Saudi Arabia step-down wholly owned subsidiary to help it avail fund-based and non-fund-based credit facilities. This supersedes an earlier May 19, 2026 approval given for the Saudi joint venture.
Likely market impact
Up to 2% potential equity dilution from ESOP. INR 70 Cr support for Saudi subsidiary aids overseas expansion but may raise contingent liability for the parent.